Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

(2010) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations

(2009) J. M. Pagel et al.   BLOOD

Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study

(2009) Yuni K. Dewaraja et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

(2009) A. M. Evens et al.   CLINICAL CANCER RESEARCH

Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma

(2009) Thomas Cazaentre et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

(2009) Jane N. Winter et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma

(2009) Michael Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative PCR Analysis forBcl-2/IgHin a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma

(2009) Lindsey Goff et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma

(2009) R. M. Sharkey et al.   JOURNAL OF NUCLEAR MEDICINE

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

(2008) T. M. Illidge et al.   BLOOD

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab

(2008) A. K. Gopal et al.   BLOOD

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

(2008) Pier Luigi Zinzani et al.   CANCER

Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma

(2008) S. A. Jacobs et al.   CLINICAL CANCER RESEARCH

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography

(2008) C. Bodet-Milin et al.   HAEMATOLOGICA

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation

(2008) Liliana Devizzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review

(2008) Frederic Peyrade et al.   LEUKEMIA & LYMPHOMA

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

(2007) Amrita Krishnan et al.   JOURNAL OF CLINICAL ONCOLOGY